Drug Discovery World
SEPTEMBER 29, 2022
Many companies have several projects ongoing simultaneously, which can limit internal resources (space, lab equipment, personnel) and delay progress. The company has the resources to complete the project in-house or it could outsource it to CROs. protein-protein or small molecule-target interactions).
Drug Discovery World
APRIL 27, 2023
Dr Mansley also comments that the multitude of biotech and pharma companies in the Greater Boston region means that people regularly move organisations. She said: “When one of our customers leaves a company and moves to a new one up the street, they often get in touch with us, which helps us grow new business.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.
DrugBaron
JANUARY 31, 2024
Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.
PerkinElmer
FEBRUARY 18, 2021
By a 3:1 margin, PerkinElmer found top Pharma screens for a specific target. Small molecules are making a comeback. For the minority of companies working with large molecules and biologics, most said they were in a phase of clinical research. The top five companies may run more than 20 screening campaigns a year.
The Pharma Data
DECEMBER 17, 2020
Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. AB2 Bio – Swiss pharma company AB2 Bio Ltd. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.
Drug Discovery World
JANUARY 3, 2023
In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities.
Expert insights. Personalized for you.
130 
Let's personalize your content